Big PFE news day today.
Have PFun!
BigKNY3
1st Qt EPS
EPS met analysts' consensus of $0.53. However, the sale of Valleylab minus the Celebra milestone payment added +$.02. Accordingly, the EPS due to ongoing business was $0.51 ....which may have disappointed some analysts. Here are some highlights from the PFE press releases.
-No Viagra sales were recorded in the first quarter. No initial sales were reported.
-1st quarter Trovan sales were $41 million in the US.
-Foreign exchange had a negative 4.5% effect on revenue growth
-Strong sales were recorded by the Zs; Zoloft (+17%), Zithromax (+16%) and Zyrtec (+58%).
-Norvasc gains (+14%) were partially offset by Procardia XL declines (-19%).
-Alliance revenue of $150 million was strong but less than the 4th quarter,1997 ($177million). Probably reflects milestone contracts with WLA.
-Zeldox has a 90 day extension to its NDA review. The review date is now June, 1998.
-Dofetilide has a brand name: Tikosyn
-The Celebra NDA will be filed in the 3rd Qt, 1998.
Bottom line: Downward pressure may finally provide that long awaited PFE buying opportunity. Be alert!
AUA Preview
The Journal of Urology published the scientific abstracts that will be presented at the 1998 AUA Annual Meeting in June,1998.
Viagra is going to have some strong support. Here is a brief summary of three key papers:
#911
A 24 Week, Fixed-Dose Study to Assess the Efficacy and Safety of Sildenafil - Dr.Harin Padma-Nathan and the Sildenafil Study Group.
-532 patients randomized to placebo or sildenafil 25mg, 50mg, or 100mg
-Did treatment improve your erections?
% Yes
Sildenafil 100 mg 84.3%
Sildenafil 50 mg 77.4%
Sildenafil 25 mg 56.4%
Placebo 24.8%
-"Sildenafil was well-tolerated with a low rate of discontinuation from treatment due to adverse reactions (2%)...There were no serious adverse events or laboratory abnormalities that were attributed to sildenafil."
-"Conclusions- These results indicate that oral sildenafil is an effective and well-tolerated therapy for the treatment of ED of broad-spectrum etiology with efficacy maintained during long-term treatment."
#910
Meta-Analysis of the Efficacy of Sildenafil in the Treatment of Severe Erectile Dysfunction. Dr. William Steers and the Sildenafil Study Group
Data for 3,361 ED patients from 10 double-blind studies of sildenafil (50mg-100mg) were merged.
Conclusions: "The results of this meta-analysis indicate that sildenafil at doses of 50 mg and 100mg, is effective in men with severe ED, with response rates ranging from 46% to 73%."
#912
Analysis of the Efficacy of Sildenafil in the Treatment of Male Erectile Dysfunction In the Elderly- Dr. Gorm Wagner, Copenhagen
Conclusions: This analysis demonstrates that sildenafil (25-100 mg) is equally effective in the elderly (>65 years) and <65 year old men with ED.
|
